2024 Asia Conference on Lung Cancer (ACLC) - Poster & ePosters-PP02.11

PP02.11 - Lucheng Zhu
Pdf Summary
The phase 2 study aimed to evaluate the safety and effectiveness of combining almonertinib, a third-generation EGFR-TKI, with concurrent thoracic radiotherapy in patients with unresectable locally advanced non-small-cell lung cancer (NSCLC) harboring EGFR mutations. This approach was considered due to previously observed issues with radiation pneumonitis (RP) when combining first-generation EGFR-TKIs and radiotherapy.<br /><br />Conducted at Hangzhou Cancer Hospital, China, from November 2020 to December 2023, the study enrolled 16 patients. The primary endpoint was the incidence of grade 3 RP within six months post-radiotherapy, while secondary endpoints included local control rate, progression-free survival (PFS), and overall survival (OS).<br /><br />Results showed a total RP rate of 68.8% (11/16), with 6.25% (1/16) of patients experiencing grade 3 RP. Most frequent adverse events were pneumonitis, rash, and radiation esophagitis. The median PFS was 13.8 months, but the median OS was not reached during the study period. The objective response rate (ORR) was 81.3%, and the disease control rate (DCR) was 93.8%.<br /><br />The study concluded that combining almonertinib with concurrent thoracic radiotherapy is tolerable in this patient population, offering promising efficacy outcomes. However, the incidence of radiation pneumonitis remains a concern. Further research and long-term follow-up are suggested to better understand the balance between efficacy and safety, and to confirm these findings in larger populations.